INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $504,000 | -20.3% | 5,000 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $632,000 | +150.8% | 5,000 | +66.7% | 0.01% | +166.7% |
| Q2 2018 | $252,000 | -61.7% | 3,000 | -25.0% | 0.00% | -62.5% |
| Q3 2016 | $658,000 | -45.1% | 4,000 | -52.4% | 0.01% | +14.3% |
| Q2 2016 | $1,198,000 | +90.2% | 8,400 | +71.4% | 0.01% | -12.5% |
| Q1 2016 | $630,000 | -20.5% | 4,900 | -7.5% | 0.01% | -27.3% |
| Q4 2015 | $792,000 | -78.2% | 5,300 | -75.8% | 0.01% | -77.6% |
| Q3 2015 | $3,635,000 | -44.9% | 21,915 | -19.9% | 0.05% | -37.2% |
| Q2 2015 | $6,602,000 | -26.8% | 27,350 | -14.5% | 0.08% | -26.4% |
| Q1 2015 | $9,019,000 | +345.2% | 31,980 | +146.2% | 0.11% | +381.8% |
| Q4 2014 | $2,026,000 | -41.8% | 12,990 | -11.7% | 0.02% | -43.6% |
| Q3 2014 | $3,482,000 | +109.6% | 14,710 | +109.5% | 0.04% | +143.8% |
| Q2 2014 | $1,661,000 | -9.8% | 7,020 | +25.7% | 0.02% | -33.3% |
| Q1 2014 | $1,842,000 | – | 5,585 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |